AFP and liver cancer: AFP was also positively correlated with sensitivity of liver cancer cells to three combined regimens containing oxaliplatin (L-OHP) and epirubicin (EPI) : L-OHP + EPI + irinotecan + 5-fluorouracil (5-FU), L-OHP + irinotecan + EPI, and L-OHP + EPI (χ2 = 8.168, P=0.004, χ2 = 5.705, P=0.017, and χ2 = 8.275, P=0.004, respectively).